Under the gaze of everyone, Park Jin Hyuk said:

DS BioLogics' production capacity has reached its limit, so we came up with these plans. ... In addition, we will need to produce North's new drug later, which will also require some production capacity."

"Under the circumstances, do you still want to produce North's new medicine? Do you have the spare capacity?"

"North's new drug has completed Phase 3 clinical trials and received FDA approval for trial production. FDA officials will soon visit Bio Logics to inspect its production facilities."

"Is there really any need to be so nervous? The demand for Bidaphil is already huge, so where is the production capacity to produce North's new drug?"

Park Jin Hyuk looked at his father.

Park Junwan insisted on asking this question even though he knew the answer, and it seemed that he was doing it intentionally for everyone present to hear.

Park Jin Hyuk looked at the participants and said:

"Although we have obtained the Asian sales rights for Bidaphil, our cooperation with Novo Nordisk Pharmaceuticals only covers contract manufacturing and partial sales rights. However, with Novo Nordisk's new drug, the entire supply chain, from raw material procurement to production and sales, is under DS Pharmaceuticals' control. If Bidaphil's annual sales can reach 400 billion won (approximately 2.1 billion RMB), Novo Nordisk's new drug sales could reach 1 trillion won (approximately 5.3 billion RMB), and the difference in operating profit will be even greater."

Park Junwan said:

"Then we really should be prepared. Will there be any problems with the FDA's production approval?"

"As long as there are no major problems with the factory inspection, we will definitely be able to obtain a production license."

"Great! BioLogics is developing rapidly. It seems we made the right decision to abandon the transfer. I didn't expect it to develop so well. The market has a very good evaluation of pharmaceuticals. I heard that the stock price has been rising."

Park Junwan looked at Mao Dayong.

Mao Dayong smiled and replied:

"In the past three months, DS Pharmaceuticals' stock price has risen 300%, and that was before BioLogics went public."

"Well, it looks like Bio Logics needs to start going public. President Mao, take advantage of the current favorable situation and prepare for the listing."

"Yes, I'll start preparing right away. We can first list on the relatively easy SME board, then transfer to the comprehensive stock market, or go public through a merger or backdoor listing. We will find a suitable method."

"If you go public at this point, you can raise a lot of funds, so don't miss the opportunity."

After Park Junwan finished his comments, it was the DS construction report's turn next.

Xuan Yizhu walked forward and began to report on the business situation.

"Compared to the same period last year, DS Construction's operating profit increased by 500%. We stopped some projects with poor input-output ratios. Since our business in Qatar is based on advance payments, our operating profit has increased significantly."

The attention of the participants began to focus on Park Jin Hyuk, so everyone knew that Park Jin Hyuk made an indelible contribution to the performance improvement of DS Construction and DS Pharmaceuticals.

Xuan Yizhu continued:

"DS Construction has limited room for development in China. Starting this year, we will focus our business expansion overseas. In this regard, we sincerely ask for the support of all the presidents present!"

After hearing this, the participants responded:

"The success of DS Construction will benefit the group as a whole. Don't worry! We will provide support."

"I can feel the changes in DS construction at every monthly meeting. It's very encouraging."

Amidst the praise, Park Junwan raised a question:

"If we want to expand our business overseas, I'm afraid it will be very difficult to rely solely on our own business development capabilities. Do you have any good solutions?"

"You're absolutely right. Therefore, we are currently planning to form a consortium with other companies to steadily expand our overseas business."

"Consortium? Do you mean with Dongjing Industry?"

As he said this, he glanced at Park Jin Hyuk.

Xuan Yizhu said:

"We are not only collaborating with Dongjing Industry, but we will also consider cooperating with them no matter who they are, as long as they can help us."

"Well, the DS construction has changed a lot."

"This is all thanks to Executive Director Park, who laid a solid foundation for DS through organizational restructuring."

Park Junwan looked around at the participants and said:

"DS Construction has not only overcome its operational difficulties but is also showing momentum for expansion. This year's performance is worth looking forward to. Furthermore, DS BioLogics' capacity utilization has increased from 60% to 100%, which still fails to meet customer demand. I am very pleased to see these changes."

Park Junwan smiled and glanced at Park Jinhyuk.

His smile was intentionally meant for others to see, and these others were Park Soo-wan and Park Kyung-wan who were sitting opposite him.

After saying that, Park Junwan stood up.

"Director Park, come to my office for a moment."

Seeing his father walk out of the meeting room, Park Jin Hyuk sat there without moving.

He didn't know whether to be happy or to keep silent.

Xuan Yizhu and Mao Dayong came over. Xuan Yizhu whispered first:

"Manager Park, was I too conservative about the cooperation with Dongjing Industry just now?"

"You're right. We never intended to rely on Dongjing Industry. It would be difficult for our opponents to deal with this kind of mix of truth and falsehood."

"Understood."

Then, Mao Dayong said:

"You didn't allow me to mention the new drug development plan, so I didn't mention it, but wouldn't it be better to mention it?"

"We are still in the preparation stage of new drug development, so there is no need to announce it so early. We have already achieved a lot recently."

Previously, DS Pharmaceuticals’ products have always been mainly nutritional supplements, but now it is finally gradually getting on the right track as a pharmaceutical company.

For a pharmaceutical company, the ability to develop new drugs is essential.

"We don't have the technical capabilities to develop new drugs. We need to look outside for collaboration or mergers and acquisitions. President Mao, please select some partners first, and then we can discuss further."

"OK."

When judging a pharmaceutical company's technological capabilities, Park Jin Hyuk can use his special ability to identify value.

If you want to see quick results, cooperating with or acquiring companies like North that have R&D capabilities is a good way.

DS Pharmaceuticals' current business includes the production of new drugs such as Bidaphil and North, and the Telasma generic drug business that is undergoing clinical trials.

With the track record of producing Bifida, DS Pharmaceuticals no longer had any problems with the contract with Pfizer Pharmaceuticals. Coupled with the new drug development plan, DS Pharmaceuticals' development blueprint gradually emerged.

Listening to the conversation between Mao Dayong and Park Jin Hyuk, Xuan Yizhu said with regret:

"Manager Park, don't you regret it?"

"What do you mean by that?"